Skip to main content

Table 3 Percent antibiotic susceptibility of Acinetobacter spp. and P. aeruginosa during 2015/2016 compared to corresponding susceptibility results in 2011/2013a

From: A compilation of antimicrobial susceptibility data from a network of 13 Lebanese hospitals reflecting the national situation during 2015–2016

Antibiotic

Acinetobacter spp

P. aeruginosa

2011/2013 N (% S)

2015/2016 N (% S)

OR (95% CI)

P

2011/2013 N (% S)

2015/2016 N (% S)

OR (95% CI)

P

Amikacin

3329 (16%)

3675 (19%)

1.23 (1.11–1.36)

0.0001

7675 (89%)

9005 (85%)

0.70 (0.62–0.79)

0.0001

Aztreonam

NA

NA

NA

NA

7483 (76%)

7457 (79%)

1.19 (1.06–1.33)

0.002

Cefepime

3409 (13%)

3675 (13%)

1.00 (0.89–1.12)

1

7897 (83%)

9005 (81%)

0.87 (0.79–0.97)

0.01

Ceftazidime

3343 (12%)

3675 (13%)

1.10 (0.973–1.23)

0.14

7897 (82%)

9005 (80%)

0.88 (0.79–0.97)

0.01

Ciprofloxacin

3379 (12%)

3675 (11%)

0.91 (0.80–1.02)

0.12

7897 (77%)

9005 (73%)

0.81 (0.74–0.89)

0.0001

Gentamicin

3384 (19%)

3675 (14%)

0.70 (0.62–0.78)

0.0001

7722 (83%)

9005 (81%)

0.87 (0.79–0.97)

0.01

Imipenem

3409 (18%)

3675 (12%)

0.62 (0.56–0.70)

0.0001

7897 (73%)

9005 (70%)

0.86 (0.79–0.94)

0.001

Piperacillin/tazobactam

3343 (13%)

3675 (11%)

0.83 (0.73–0.93)

0.12

7897 (80%)

9005 (78%)

0.89 (0.80–0.98)

0.02

  1. KEY = CI confidence interval, N Number of isolates tested in each bacteria/antibiotic combination, NA not available, OR Odds Ratio, S Susceptibility, % percent
  2. P < 0.05 is considered statistically significant
  3. aThe 2011/2013 data are taken from: Chamoun K, Farah M, Araj G, et al. Surveillance of antimicrobial resistance in Lebanese hospitals: retrospective nationwide compiled data. Int J Infect Dis. 2016;46:64–70